APA način citiranja (7. izdanje)

(16384177), T. P. D., (16384180), K. W. E., (15107821), M. G. R., (16384183), M. Z., (16384186), Y. Q. R., (16384189), X. Z., . . . (10258780), F. M. (2025). Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.

Čikaški stil citiranja (17. izdanje)

(16384177), Timothy P. DiPeri, et al. Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. 2025.

MLA način citiranja (9. izdanje)

(16384177), Timothy P. DiPeri, et al. Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. 2025.